Data / Drug companies / Exelan Pharmaceuticals Inc.
Exelan Pharmaceuticals Inc.: 178 products in the FDA NDC directory, labeler code 76282
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Exelan Pharmaceuticals Inc. (labeler code 76282) lists 178 products in the FDA National Drug Code Directory, covering 61 finished drugs by generic name. By type: 174 prescription drugs, 4 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 11, 2026.
The request: Watch Exelan Pharmaceuticals Inc. (FDA labeler code 76282): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 76282
- Products in commercial distribution
- 178
- Packages
- 423
- Finished drugs by generic name
- 61
- Prescription products
- 174
- Over the counter products
- 4
- Controlled substance products
- Schedule V 13
- Flagged as original packager
- 173 of 173 products that carry the flag
- Started marketing in the last 12 months
- 12
- Earliest marketing start
- June 21, 2005
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 178 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 174 | 97.8% |
| Over the counter drugs | 4 | 2.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 84 | 47.2% |
| Capsule | 38 | 21.3% |
| Tablet, film coated | 34 | 19.1% |
| Inhalant | 4 | 2.2% |
| Film, extended release | 3 | 1.7% |
| Tablet, extended release | 3 | 1.7% |
| Tablet, chewable | 3 | 1.7% |
| Injection | 3 | 1.7% |
| Tablet, coated | 2 | 1.1% |
| Gel | 1 | 0.6% |
| For suspension | 1 | 0.6% |
| Injection, powder, lyophilized, for suspension | 1 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Paclitaxel 100mg per vial | 76282-768 | Injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | August 11, 2026 |
| Brivaracetam | 76282-826 | Tablet, film coated | Generic drugs (ANDA) | July 28, 2026 |
| Brivaracetam | 76282-825 | Tablet, film coated | Generic drugs (ANDA) | July 28, 2026 |
| Brivaracetam | 76282-824 | Tablet, film coated | Generic drugs (ANDA) | July 28, 2026 |
| Brivaracetam | 76282-823 | Tablet, film coated | Generic drugs (ANDA) | July 28, 2026 |
| Brivaracetam | 76282-822 | Tablet, film coated | Generic drugs (ANDA) | July 28, 2026 |
| Tofacitinib | 76282-816 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 10, 2026 |
| Nintedanib Capsules, 100 mg and 150 mg | 76282-787 | Capsule | Generic drugs (ANDA) | May 7, 2026 |
| Nintedanib Capsules, 100 mg and 150 mg | 76282-786 | Capsule | Generic drugs (ANDA) | May 7, 2026 |
| Metoprolol tartrate | 76282-796 | Tablet | Generic drugs (ANDA) | February 9, 2026 |
| Metoprolol tartrate | 76282-795 | Tablet | Generic drugs (ANDA) | February 9, 2026 |
| Metoprolol tartrate | 76282-794 | Tablet | Generic drugs (ANDA) | February 9, 2026 |
| Ticagrelor | 76282-584 | Tablet, film coated | Generic drugs (ANDA) | October 29, 2025 |
| Nicotine Transdermal System | 76282-783 | Film, extended release | Generic drugs (ANDA) | October 13, 2025 |
| Nicotine Transdermal System | 76282-782 | Film, extended release | Generic drugs (ANDA) | October 13, 2025 |
| Nicotine Transdermal System | 76282-781 | Film, extended release | Generic drugs (ANDA) | October 13, 2025 |
| Rivaroxaban | 76282-774 | Tablet, film coated | Generic drugs (ANDA) | August 4, 2025 |
| Lanreotide acetate | 76282-720 | Injection | Generic drugs (ANDA) | May 30, 2025 |
| Lanreotide acetate | 76282-719 | Injection | Generic drugs (ANDA) | May 30, 2025 |
| Lanreotide acetate | 76282-718 | Injection | Generic drugs (ANDA) | May 30, 2025 |
| Ticagrelor | 76282-550 | Tablet, film coated | Generic drugs (ANDA) | May 7, 2025 |
| Cyclobenzaprine Hydrochloride | 76282-283 | Tablet | Generic drugs (ANDA) | April 10, 2025 |
| Bumetanide | 76282-799 | Tablet | Generic drugs (ANDA) | March 1, 2025 |
| Bumetanide | 76282-798 | Tablet | Generic drugs (ANDA) | March 1, 2025 |
| Bumetanide | 76282-797 | Tablet | Generic drugs (ANDA) | March 1, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.